
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx is a category leader in the bronchoscopic lung volume reduction market with a strong product portfolio, including Zephyr valves and the Chartis assessment system. While the company has faced challenges in the past, recent restructuring efforts have improved operating efficiency and narrowed losses, culminating in a solid full-year earnings report. With an upcoming earnings cycle focused on U.S. procedure growth and improved sales metrics, Pulmonx has the potential for strong revenue growth and improved profitability in the future.
Bears say
Pulmonx is facing significant risk factors and uncertainties, including clinical and regulatory challenges, financial risks, and market share challenges. While the company reported modest annual growth in its recent financial results, it also highlighted weaker quarterly performance and a transitional period. The company's future revenue growth and profitability also depend on its ability to overcome collateral ventilation limitations and successfully execute its strategy to expand its addressable market. Without solid evidence of improved sales execution, it is difficult to have a positive outlook on the company's stock.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares